[go: up one dir, main page]

WO2025074090A1 - Combinaison de cxd101 et d'un superagoniste d'il-15 pour traiter des maladies prolifératives telles que le cancer - Google Patents

Combinaison de cxd101 et d'un superagoniste d'il-15 pour traiter des maladies prolifératives telles que le cancer Download PDF

Info

Publication number
WO2025074090A1
WO2025074090A1 PCT/GB2024/052525 GB2024052525W WO2025074090A1 WO 2025074090 A1 WO2025074090 A1 WO 2025074090A1 GB 2024052525 W GB2024052525 W GB 2024052525W WO 2025074090 A1 WO2025074090 A1 WO 2025074090A1
Authority
WO
WIPO (PCT)
Prior art keywords
superagonist
cancer
cxd101
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2024/052525
Other languages
English (en)
Inventor
Nicholas La Thangue
Wojciech BARCZAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celleron Therapeutics Ltd
Original Assignee
Celleron Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celleron Therapeutics Ltd filed Critical Celleron Therapeutics Ltd
Publication of WO2025074090A1 publication Critical patent/WO2025074090A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel combination therapy and to the use of this combination therapy for the treatment of proliferative disorders, such as cancer.
  • Cancer is caused by uncontrolled and unregulated cellular proliferation. Precisely what causes a cell to become malignant and proliferate in an uncontrolled and unregulated manner has been the focus of intense research over recent decades. This research has led to the identification of a number of molecular targets and key metabolic pathways that are known to be associated with malignancy.
  • cancers may be described in terms of “hot” or “cold”, depending on whether they show signs of inflammation or T-lymphocyte infiltration.
  • Immunogically cold cancers by virtue of their low mutational burdens, low antigenic loads, and poor recognition by T-lymphocytes and other immune cells, are generally associated with poor response to immune checkpoint inhibitors, such as anti-PD-1/L1 or anti-CTLA4.
  • the present invention relates to a combination comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL-15 superagonist.
  • CXD101 N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide
  • an IL-15 superagonist a combination comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL-15 superagonist.
  • the CXD101 compound, or a pharmaceutically acceptable salt or solvate thereof is administered simultaneously, separately or sequentially with the IL-15 superagonist.
  • a pharmaceutical product comprising a combination comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL-15 superagonist.
  • a pharmaceutical composition comprising a combination of N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL- 15 superagonist, and one or more pharmaceutically acceptable excipients.
  • the fourth aspect of the invention there is provided a combination according to the first aspect of the invention, or a pharmaceutical product according to the second aspect of the invention, or a pharmaceutical composition according to the third aspect of the invention for use in therapy.
  • the use in therapy is use in the treatment of proliferative disorder, such as cancer.
  • the CXD101, or a pharmaceutically acceptable salt thereof, and the IL-15 superagonist are administered separately, sequentially or simultaneously.
  • a method of treating of a proliferative disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of (i) a combination according to the first aspect of the invention, or (ii) the pharmaceutical product according to the second aspect of the invention, or (iii) the pharmaceutical composition according to the third aspect of the invention.
  • the sixth aspect of the invention there is provided a method of potentiating the immune response against a tumour, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of (i) a combination according to the first aspect of the invention, or (ii) the pharmaceutical product according to the second aspect of the invention, or (iii) the pharmaceutical composition according to the third aspect of the invention.
  • the tumour is a cancer selected from lung, colorectal, breast, ovarian, bladder, kidney, prostate, liver, pancreas, brain, bone, blood and skin cancer.
  • N-(2-aminophenyl)-4-(1- [(1,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof for use in treating a proliferative disorder in combination with an IL-15 superagonist.
  • an IL- 15 superagonist for use in treating a proliferative disorder in combination with N-(2-aminophenyl)-4-(1-[(1,3- dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof.
  • the ninth aspect of the invention there is provided the use of a combination according to the first aspect of the invention in the manufacture of a medicament for treating a proliferative disorder.
  • N-(2- aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with an IL-15 superagonist
  • an IL- 15 superagonist in the manufacture of a medicament for treating a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administeration with N- (2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof.
  • the proliferative disorder is cancer, such as a cold cancer.
  • the cancer is selected from lung, colorectal, breast, ovarian, bladder, kidney, prostate, liver, pancreas, brain, bone, blood and skin cancer.
  • the cancer is a cold cancer.
  • kits comprising two separate formulations to be used together, the formulations being: a first formulation comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient; and a second formulation comprising an IL-15 superagonist and at least one pharmaceutically acceptable excipient.
  • a first formulation comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient
  • a second formulation comprising an IL-15 superagonist and at least one pharmaceutically acceptable excipient.
  • the IL-15 superagonist is selected from: N-803, het-IL-15, receptor-linker-IL-15 (RLI), and IL-15/IL-15Ra-Fc; preferably, the IL-15 superagonist is N-803.
  • references to “treating” or “treatment” include prophylaxis as well as the alleviation of established symptoms of a condition.
  • “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • a “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
  • a “pharmaceutically acceptable salt” of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- yl)methyl]piperidin-4-yl)benzamide refers to any salt form suitable for pharmaceutical use.
  • Examples of pharmaceutically acceptable salts include an acid-addition salt of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin- 4-yl)benzamide (CXD101/zabadinostat), for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoracetic, formic, citric methane sulfonate or maleic acid.
  • an inorganic or organic acid for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoracetic, formic, citric methane sulfonate or maleic acid.
  • references herein to N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- yl)methyl]piperidin-4-yl)benzamide include, where appropriate, any isomeric, tautomeric, polymorphic, amorphous and solvate (e.g. hydrate) forms of the inhibitors.
  • N-(2-aminophenyl)-4-(1-[(1,3- dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide may also be administered in the form of a prodrug which is broken down in the human or animal body to release the active inhibitor.
  • pro-drugs include in vivo cleavable ester derivatives of the inhibitors that may be formed at a carboxy group or a hydroxy group in an inhibitor compound and in-vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in an inhibitor compound.
  • pro-drug Various forms of pro-drug have been described, for example in the following documents :- a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter s “Design and Application of Pro-drugs”, by H. Bundgaard p. US- 191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H.
  • “simultaneous administration” refers to therapy in which the both agents (e.g., N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4- yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solvate thereof, and IL-15 superagonist) are administered at the same time, suitably as a monotherapy.
  • agents e.g., N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4- yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solvate thereof, and IL-15 superagonist
  • sequential administration means that one agent is administered after the other, however, the time period between the administration of each agent is such that both agents are capable of acting therapeutically concurrently.
  • administration “sequentially” may permit one agent to be administered within seconds, minutes, or a matter of hours after the other provided the circulatory half-life of the first administered agent is such that they are both concurrently present in therapeutically effective amounts.
  • the time delay between the administration of the agents may vary depending on the exact nature of the agents, the interaction there between, and their respective half-lives.
  • separate administration means that one agent is administered after the other, however, the time period between administration is such that the first administered agent is no longer present a therapeutically effective amount when the second agent is administered. Accordingly, the two agents exert their therapeutic effects separately. Nevertheless, the overall therapeutic effect observed when the two agents separately act therapeutically may be greater than either agent used alone.
  • mammals e.g., humans and non-human mammals such as livestock (cows, sheep, goats) or companion animals (cats, dogs, horses, rabbits).
  • the subject(s) and/or patient(s) are human(s).
  • a “pharmaceutical product” refers to a product comprising a pharmaceutical.
  • examples of a pharmaceutical product include a medical device, a pharmaceutical composition and a kit of parts suitably comprising one or more devices, containers and/or pharmaceuticals.
  • potentiate means that any of the mentioned activities of the compound embodied herein, are, e.g., increased, enhanced, promoted. Potentiation can increase activity more than 1-fold, 2-fold, 3-fold, 5-fold, 10-fold, 100-fold, etc., over baseline values.
  • CXD101/zabadinostat is a Class l-selective histone deacetylase (HDAC) inhibitor with specificity for Class I isoforms HDAC1 (62 nM IC50), HDAC2 (570 nM IC50), and HDAC3 (550 nM IC50), and no activity (>2500 nM) against HDAC Class II 1 .
  • HDAC histone deacetylase
  • CXD101/zabadinostat N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H- pyrazol-4-yl)methyl]piperidin-4yl)benzamide. It has a molecular weight of 403.52, and formula C24H29N50.
  • CXD101/zabadinostat is a white or off-white crystalline solid. It is dibasic with a pKas of 3.2 and 9. It displays pH-dependent solubility, with a solubility of 0.5 mg/mL to >20 mg/mL across the pH range 1 to 8 at 25°C.
  • the melting point of CXD101/zabadinostat is approximately 172°C.
  • the UV absorbance maxima are 199 and 229 nm.
  • CXD101/zabadinostat The structure of CXD101/zabadinostat is shown below:
  • the CXD101/zabadinostat compound is suitably administered orally, optionally in the form of a tablet or capsule (for example, a tablet or capsule containing 0.25 to 40 mg of CXD101/zabadinostat, such as 0.5 mg to 30 mg, 0.5 to 20 mg, 0.5 to 10 mg, or 0.5 to 5 mg).
  • the dosage for the CXD101/zabadinostat compound will be 0.5-40 mg per day optionally in a divided dose, such as 1-30 mg per day optionally in a divided dose, 1-20 mg per day optionally in a divided dose, or 1-10 mg per day optionally in a divided dose.
  • the CXD101/zabadinostat compound is adminstered twice daily.
  • zabadinostat sequesters the Zn 2+ ion required for the hydrolysis and removal of the acetyl group from lysine residues, preventing substrate deacetylation.
  • zabadinostat is chemically distinct from earlier generations of less selective pan-HDAC inhibitors, such as vorinostat, belinostat and panobinostat, which bind Zn 2+ ions through their hydroxamic acid groups 2 .
  • Zabadinostat is being investigated as a treatment for late-stage cancers, including relapsed or refractory lymphoma, microsatellite stable colorectal cancer, and hepatocellular carcinoma, the most common form of liver cancer.
  • NCT01977638 A Phase I clinical trial conducted in late-stage cancer patients unresponsive to conventional therapy found that zabadinostat treatment resulted in anti-cancer responses for follicular lymphoma (FL), classic Hodgkin lymphoma (HL), and peripheral T-cell lymphoma (PTCL).
  • FL follicular lymphoma
  • HL classic Hodgkin lymphoma
  • PTCL peripheral T-cell lymphoma
  • the most common Grade 3 and above treatment-related adverse events (TRAE) were neutropenia (17%), thrombocytopenia (11%) and leukopenia (5%).
  • Serious adverse events (SAE) were infrequent, and included neutropenic fever (3%), fatigue (1.5%), anorexia ( ⁇ 1%), diarrhoea ( ⁇ 1%), and bronchial infection ( ⁇ 1%). No treatment-related deaths occurred on study.
  • the recommended Phase 2 dose (RP2D) was found to be 20 mg twice daily (b.i.d.) 1
  • NCT03993626 Phase II clinical trial combining zabadinostat and nivolumab showed that it was effective in treating metastatic microsatellite-stable (MSS) colorectal cancer patients who had progressed despite receiving at least two lines of systemic anticancer therapies.
  • MSS metastatic microsatellite-stable
  • the combination therapy was well tolerated with the most frequent Grade 3 or 4 adverse events being neutropenia (18%) and anaemia (7%).
  • Immune-related adverse reactions commonly ascribed to checkpoint inhibitors were surprisingly rare although single cases of pneumonitis, hypothyroidism and hypopituitarism were seen. There were also no treatment-related deaths.
  • mice showed that zabadinostat treatment altered their tumour microenvironment (TME), attracting CD4+ and CD8+ tumour-infiltrating T lymphocytes, and enhancing anti-tumour activity, especially when combined with immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA4 4 .
  • TAE tumour microenvironment
  • ICIs immune checkpoint inhibitors
  • zabadinostat increased expression of MHC class I and II genes in a variety of cells, including dendritic cells (DCs) and healthy tissue, enhanced the activity of DCs, and CD4 and CD8 T lymphocytes, and enhanced humoral response reflected increased activity of T follicular helper (Tfh) cells and germinal centre (GC) B cells.
  • DCs dendritic cells
  • Tfh T follicular helper
  • GC germinal centre
  • Interleukin- 15 is a member of the common receptor gamma chain (yc) family, which is a group of cytokines with broad pleiotropic activity on both the innate and adaptive immune systems.
  • IL-15Ra is not a signalling receptor for IL-15 but is critical for IL-15 biological activity 6 .
  • the IL-15Ra transmembrane receptor binds intracellularly to IL-15, facilitating its trafficking and cell surface expression as I L-15/I L-15Ra heterodimer complexes, which can also be cleaved from the cell surface 6 .
  • membranebound I L-15/I L-15Ra complexes are presented in trans to cells that express the receptor complex 5 .
  • IL-15 preferentially stimulates activation, proliferation, survival, and cytotoxicity of NK and CD8+ T cell populations, including regulation of memory CD8+ T cell homeostatic proliferation and survival 5 .
  • rlL-15 soluble recombinant IL-15 was initially examined for therapeutic potential.
  • rlL-15 promoted significant anti-tumour efficacy associated with enhanced CD8+ T and NK cell function 7 .
  • rlL-15 The efficacy of rlL-15 is limited by its short half-life due to instability, ranging from ⁇ 1 hour in mice and 2.5 to 12 hours in patients depending on the route of administration [7-9], and IL- 15Ra availability in vivo.
  • IL-15 therapy To improve the therapeutic potential of IL-15 therapy, several types of I L- 15/I L- 15Ra complexes were developed.
  • IL-15 superagonist or IL-15 superagonist complex refers to a type of agonist that is capable of producing a maximal response greater than the endogenous agonist for the target receptor, in this case, the IL-15 receptor.
  • heterodimeric (het) IL-15 1. heterodimeric (het) IL-15,
  • N-803 is described in WO2018183821 (Aitor Bioscience Corporation) and US 8163,879 (Aitor Bioscience Corporation).
  • Het IL-15 is described in WO2015103928 (SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD and JIANGSU HENGRUI MEDICINE CO., LTD).
  • Receptor-linker-IL-15 (RLI) is described in WO2012175222 (Cytune and INSERM).
  • IL-15/IL-15Ra-Fc is described in WO2019204592 (Xencor Inc.).
  • IL-15 superagonist Any IL-15 superagonist may be used in the aspects of the invention described herein.
  • the I L-15 superagonist for use in any of the aspects of the invention described herein is N-803.
  • N-803 (also known as ALT-803) is an IL-15 superagonist in clinical development with therapeutic potential against solid cancers and haematological malignancies. It consists of an IL-15 superagonist mutein (IL-15N72D) and a dimeric IL-15 receptor alpha (I L-15Ra)/Fc fusion protein. In vitro, N-803 increased human NK-mediated cytotoxicity against B cell lymphoma, head and neck, lung, and breast carcinoma cells, including in the presence of cetuximab (anti- EGFR) or avelumab (anti-PD-L1) 8 .
  • cetuximab anti- EGFR
  • anti-PD-L1 avelumab
  • N-803 restricted tumour growth and improved the median overall survival (mOS) of mice with colon and breast tumours, among others 11 .
  • IL- 15 superagonists appear to have an advantage over rlL- 15 in mediating immune effects, specifically, greater expansion of NK and CD8+ T cells, without inducing significant toxicity.
  • N-803 is currently being investigated in clinical trials to treat patients with bladder cancer, myeloma, melanoma and other relapsed hematological malignancies. It is well characterised clinically and is described as well tolerated with no dose-limiting toxicity.
  • IL-15 heterodimer comprises a complex of the IL-15 chain with the IL-15 receptor alpha (IL-15Ra) chain. It closely resembles the natural form of the cytokine produced in vivo.
  • IL-15/IL-15Ra-Fc comprises a pre-association of IL-15, IL-15Ra, and the Fc portion of human lgG1, which enhances the activities of IL-15 in vivo. It greatly enhances the proliferation of NK cells and CD8 T lymphocytes.
  • Receptor-linker-IL-15 is a fusion molecule of human IL-15 covalently linked to the human IL-15Ra sushi+ domain. It is currently assessed in clinical trials as a treatment for patients with advanced/metastatic solid cancer.
  • the IL-15 superagonist for use in the present invention is selected from N-803, het-IL-15, receptor-linker-IL-15 (RLI), and IL-15/IL-15Ra-Fc.
  • the preferred IL-15 superagonist is N-803.
  • the present invention resides in the recognition that N-(2-aminophenyl)-4-(1-[(1,3-dimethyl- 1H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat) and the IL15 superagonist N-803 act synergistically in an art recognised mouse colon cancer model. Indeed, as shown in the examples the combination was capable of effectively shrinking the tumour volume. Based on their mode of action, it is expected that other IL-15 superagonists will also act syergistically with CXD101.
  • the combination treatment or therapy of the present invention has the potential to provide better outcomes in cancer patients.
  • the present invention relates to a combination comprising N-(2- aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL-15 superagonist.
  • the CXD101 compound, or a pharmaceutically acceptable salt or solvate thereof is administered simultaneously, separately or sequentially with the IL-15 superagonist.
  • the IL-15 superagonist is selected from N-803, het-IL-15, receptor-linker-IL-15 (RLI), and IL-15/IL-15Ra-Fc.
  • the preferred IL-15 superagonist is N-803.
  • the IL-15 superagonist is N-803.
  • the N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, is administered at dosage of 20mg to 40mg per day.
  • N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof is administered at dosage of 10 to 20 mg twice a day.
  • the N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, is administered for 2 to 8 consecutive days in a two or three period and this dosing schedule is optionally repeated.
  • N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, is administered for 5 consecutive days in a two or three week period and this dosing schedule is optionally repeated.
  • the N-803 is administered subcutaneously, at a clinical dosage between 0.9 mg to 1.1 mg, on Days 1 and 15 of a 15-day treatment cycle.
  • zabadinostat CXD101
  • CXD101 zabadinostat
  • a pharmaceutical product comprising a combination of N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL-15 superagonist.
  • the IL-15 superagonist is selected from N-803, het-IL-15, receptor-linker-IL-15 (RLI), and IL-15/IL-15Ra-Fc.
  • the preferred IL-15 superagonist is N-803.
  • the IL-15 superagonist is N-803.
  • the pharmaceutical product may comprise a kit of parts comprising separate formulations of N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solavte thereof, and the IL-15 superagonist.
  • kit of parts comprising separate formulations of N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solavte thereof, and the IL-15 superagonist.
  • N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solvate thereof, and the IL- 15 superagonist, may be administered sequentially, separately and/or simultaneously.
  • the pharmaceutical product is a kit of parts which comprises: a first container comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1 H-pyrazol-4- yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier; and a second container comprising an IL-15 superagonist; and a container means for containing said first and second containers.
  • the pharmaceutical product may comprise a one or more unit dosage forms (e.g. vials, tablets or capsules in a blister pack).
  • one unit dose comprises N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4- yl)benzamide (CXD101/zabadinostat) compound, or a pharmaceutically acceptable salt or solvate thereof, and the other unit dosage form is the IL- 15 superagonist.
  • the unit dosage form comprises both the N-(2-aminophenyl)-4-(1-[(1,3- dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat) compound, or a pharmaceutically acceptable salt or solvate thereof, and the IL-15 superagonist (e.g., N-803).
  • the CXD101 compound, or a pharmaceutically acceptable salt or solvate thereof is administered orally and the IL-15 superagonist (e.g., N-803) is administered parenterally.
  • the IL-15 superagonist e.g., N-803
  • the pharmaceutical product is a pharmaceutical composition.
  • kits comprising two separate formulations to be used together, the formulations being: a first formulation comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient; and a second formulation comprising an IL-15 superagonist and at least one pharmaceutically acceptable excipient.
  • a first formulation comprising N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient
  • a second formulation comprising an IL-15 superagonist and at least one pharmaceutically acceptable excipient.
  • the CXD101/zabadinostat agent is administered orally.
  • the IL-15 superagonist agent is administered pareterally, e.g, intravenously, intramuscularly or subbcutaneously.
  • the pharmaceutical product or kit of parts further comprises means for facilitating compliance with a dosage regimen, for instance instructions detailing how to administer the combination.
  • a pharmaceutical composition comprising a combination of N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL- 15 superagonist, and one or more pharmaceutically acceptable excipients.
  • the IL-15 superagonist is selected from N-803, het-IL-15, receptor-linker-IL-15 (RLI), and IL-15/IL-15Ra-Fc.
  • the preferred IL-15 superagonist is N-803.
  • the IL-15 superagonist is N-803.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or
  • the pharmaceutial composition is in a form suitable for administration orally, such as in a tablet, capsule, solution or the like, or by injection, for example for subcutaneous, intramuscular, intradermal, or in a form suitable for intranasal administration.
  • compositions of the invention will typically be for parenteral administration when the agent is proteinaceous in nature.
  • the IL- 15 superantagonist is proteinaceous.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration.
  • An effective amount of a combination of an N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, or an IL- 15 superagonist for use in the combination therapy of the invention is an amount sufficient to treat a proliferative condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition.
  • the effective amount of a combination of an N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, or an IL-15 superagonist for use in the combination therapy of the invention may also be an amount sufficient to slow tumour growth, halt tumour growth or reduce the tumour mass.
  • the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • a formulation intended for subcutanous administration to humans will generally contain, for example, from 0.1 mg to 1 g of active agent (more suitably from 0.5 to 2 mg, for example from 0.9 to 1.1 mg, or 15 pg/kg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • the size of the dose for therapeutic purposes of a combination of the invention will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.
  • a combination of the invention for therapeutic purposes it will generally be administered with a therapeutically effective dose of the particular I L-15 superagonist selected.
  • These dosages are known in the art and will vary from one agent to another.
  • the dosage may, for example, be in the range of 0.1 mg/kg to 30 mg/kg body weight.
  • the doing schedule will also vary from one I L-15 superagonist complex agent to another. Suitable doing schedules are known in the art.
  • the CXD101 compound is suitably administered orally, optionally in the form of a tablet or capsule (for example, a tablet or capsule containing 10mg of CXD101).
  • the dosage for the CXD101 compound will be 20-40mg per day.
  • the daily dose is administered in divided doses, with a twice daily dosing schedule being generally preferred.
  • CXD101 is suitably dosed for 2 to 8 consecutive days, more suitably 3 to 7 consecutive days and most suitably for 5 consecutive days over a two or three week period. This dosing schedule can be repeated on a two or three week cycle throughout the duration of therapy.
  • the CXD101 compound is administered at a dosage of 10-20mg twice daily for 3 to 7 consecutive days of a two or three week cycle and the therapy is continued for the duration of the therapy.
  • the CXD101 compound is administered at a dosage of 10-20mg twice daily for 5 consecutive days of a two or three week cycle (i.e. 5 days of treatment followed by 9 days with no treatment in a two week cycle and 16 days without treatment in a three week cycle) and the therapy is continued for the duration of the therapy.
  • the N-803 superagonist is administered at a dosage of 0.5 to 2 mg on Days 1 and 15 of a 15-day cycle and the therapy is continued for the duration of the therapy.
  • Both the dosage and treatment days may be modified, altered, or combined with other agents based on clinical assessment of addition benefit to safety, efficacy, or ease of administration.
  • the present invention relates to a combination as herein described, a pharmaceutical product as herein described, or a pharmaceutical composition as herein described for for use in the treatment of a proliferative disorder.
  • the present invention relates to a combination comprising N-(2-aminophenyl)- 4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, and an IL- 15 superagonist as defined herein, for use in the treatment of a proliferative disorder.
  • the present invention relates to a combination as herein described, a pharmaceutical product as herein described, or a pharmaceutical composition as herein described for for use in the treatment of a proliferative disorder in a subject.
  • proliferative disorder is used herein to refer to an unwanted, uncontrolled and abnormal cellular proliferation, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo.
  • proliferative conditions include, but are not limited to, benign, pre- malignant and malignant cellular proliferation, including but not limited to, malignant neoplasms and tumours, cancers, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), and atherosclerosis. Any type of cell may be treated, including but not limited to, lung, colon, breast, ovarian, prostate, liver, pancreas, brain, bladder, kidney, bone, nerves and skin.
  • the proliferative disorder is a benign disorder, such as, for example, neuroblastoma or fibrosis.
  • the anti-proliferative effects of the combination therapy of the present invention has particular application in the treatment of human cancers.
  • the combination therapy of the present invention will be useful for treating any human cancer in which immune cells, such as Natural Killer cells or T lymphocytes are lacking or display low activity, or in the case of cold tumours, in which the lack of antigenic presentation results in poor detection by such immune cells.
  • immune cells such as Natural Killer cells or T lymphocytes are lacking or display low activity, or in the case of cold tumours, in which the lack of antigenic presentation results in poor detection by such immune cells.
  • the proliferative disorder is cancer.
  • the anti-tumour effects of the combination therapy of the present invention has particular application in the treatment and/or prevention of a wide range of cancers including, but not limited to, non-solid tumours such as leukaemia, for example acute myeloid leukaemia, multiple myeloma, haematologic malignancies or lymphoma, and also solid tumours and their metastases such as melanoma, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, glioblastoma, carcinoma of the thyroid, bile duct, bone, gastric, brain/CNS, head and neck, hepatic, stomach, prostate, breast, renal, testicular, ovarian, skin, cervical, lung, muscle, neuronal, oesophageal, bladder, lung, uterine, vulval, endometrial, kidney, colorectal, pancreatic, pleural/peritoneal membranes, salivary gland, and epidermoid
  • non-solid tumours
  • the cancer is selected from the group consisting of: leukaemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer (including melanoma), oral squamous cell carcinoma, urinary bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, brain cancer, pancreatic cancer, colon cancer, colorectal cancer and gynaecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer and cervical cancer, including epithelia cervix carcinoma.
  • the cancer is leukaemia and can be selected from the group consisting of acute lymphoblastic leukaemia, acute myelogenous leukaemia (also known as acute myeloid leukaemia or acute non-lymphocytic leukaemia), acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia (also known as chronic myeloid leukaemia, chronic myelocytic leukaemia or chronic granulocytic leukaemia), chronic lymphocytic leukaemia, monoblastic leukaemia and hairy cell leukaemia.
  • the cancer is acute lymphoblastic leukaemia.
  • the cancer is lymphoma, which may be selected from the group consisting of: Hodgkin’s lymphoma; non-Hodgkin lymphoma; Burkitt’s lymphoma; and small lymphocytic lymphoma.
  • the cancer is a cold cancer.
  • a cold cancer also known as a cold tumour, is an abnormal, uncontrolled tissue growth (neoplasm) that has the ability or potential to spread to secondary sites (metastasize) and is difficult to detect by immune cells (for example, T-lymphocytes and Natural Killer cells).
  • Cold cancers are characterised by low mutational burdens, low antigenic loads, and poor NK and T-cell infiltration. Usually, they show low or no response to immune therapy agents, such as checkpoint inhibitors, for example, anti-PD1/L1 or anti-CTLA4 therapies.
  • the cancer is is selected from from lung, colorectal, breast, ovarian, bladder, kidney, prostate, liver, pancreas, brain, bone, blood and skin cancer.
  • the treatment of such cancers may achieve effective treatment of the cancer by preventing or treating the development of the cancer, by preventing or treating the progression of the cancer, by preventing or treating the recurrence of the cancer, by preventing or treating the propagation (including metastasis) of the cancer or by shrinking/reducing the tumour mass.
  • the agents act synergistically in the treatment of the subject, e.g., in the treatment of a proliferative disease such as cancer.
  • the agents are capable of shriking the tumour mass when administered as a combination therapy.
  • a method of treating of a proliferative disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of (i) a combination according to the first aspect of the invention, or (ii) the pharmaceutical product according to the second aspect of the invention, or (iii) the pharmaceutical composition according to the third aspect of the invention.
  • a method of treating of a proliferative disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a combination comprising N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and an IL-15 superagonist.
  • a method of treating of a proliferative disorder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and a therapeutically effective amount of an IL-15 superagonist (IL-15SA), wherein the CXD101 , or a pharmaceutically acceptable salt or solvate thereof, and the IL- ISSA are administered simultaneously, separately or sequentially.
  • CXD101 N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4- y1)methyl]piperidin-4-yl)benzamide
  • IL-15SA an IL-15 superagonist
  • the proliferative disorder is cancer.
  • the cancer is selected from the group consisting of: leukaemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer (including melanoma), oral squamous cell carcinoma, urinary bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, brain cancer, pancreatic cancer, colon cancer, colorectal cancer and gynaecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer and cervical cancer, including epithelia cervix carcinoma.
  • the cancer is leukaemia and can be selected from the group consisting of acute lymphoblastic leukaemia, acute myelogenous leukaemia (also known as acute myeloid leukaemia or acute non-lymphocytic leukaemia), acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia (also known as chronic myeloid leukaemia, chronic myelocytic leukaemia or chronic granulocytic leukaemia), chronic lymphocytic leukaemia, monoblastic leukaemia and hairy cell leukaemia.
  • the cancer is acute lymphoblastic leukaemia.
  • the cancer is lymphoma, which may be selected from the group consisting of: Hodgkin’s lymphoma; non-Hodgkin lymphoma; Burkitt’s lymphoma; and small lymphocytic lymphoma.
  • the cancer is a cold cancer.
  • the cancer is is selected from from lung, colorectal, breast, ovarian, bladder, kidney, prostate, liver, pancreas, brain, bone, blood and skin cancer.
  • a method of potentiating the immune response to a tumour comprising administering to a patient in need of such treatment a therapeutically effective amount of a combination a combination comprising N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and an IL-15 superagonist.
  • a method of of potentiating the immune response to a tumour in a subject in need thereof comprising administering to said subject a therapeutically effective amount of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and a therapeutically effective amount of an IL-15 superagonist (IL- ISSA), wherein the CXD101 , or a pharmaceutically acceptable salt or solvate thereof, and the IL-15SA are administered simultaneously, separately or sequentially.
  • CXD101 N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-y1)methyl]piperidin-4-yl)benzamide
  • IL- ISSA an IL-15 superagonist
  • a method of potentiating the immune response to a tumour comprising administering to a patient receiving treatment with an IL- 15 superagonist a therapeutically effective amount of N-(2-aminophenyl)- 4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof.
  • the amount of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof administered is effective to enhance the immune response of the IL-15 superagonist.
  • the CXD101 or a pharmaceutically acceptable salt or solvate thereof, is administered simultaneously, separately or sequentially with the and the IL-15SA.
  • the IL- 15 superagonist may be any IL- 15 superagonist as defined in any of the embodiments herein.
  • the IL-15 superagonist such as N- 803 is administered parenterally, such as intravenously.
  • the CXD101 or a pharmaceutically acceptable salt or solvate thereof, is administered orally.
  • N-(2-aminophenyl)-4-(1- [(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof for use in treating a proliferative disorder in combination with an IL-15 superagonist.
  • an IL- 15 superagonist for use in treating a proliferative disorder in combination with N-(2-aminophenyl)-4-(1-[(1 ,3- dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof.
  • the IL-15 superagonist is N- 803.
  • the ninth aspect of the invention there is provided the use of a combination comprising N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4- yl)benzamide (CXD101), or a pharmaceutically acceptable salt or solvate thereof, and an IL- 15 superagonist in the manufacture of a medicament for treating a proliferative disorder.
  • the IL-15 superagonist is N-803.
  • N-(2- aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administration with an IL-15 superagonist.
  • the IL-15 superagonist is N-803.
  • an IL- 15 superagonist in the manufacture of a medicament for treating a proliferative disorder, wherein the medicament is for simultaneous, separate or sequential administeration with N- (2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-y1)methyl]piperidin-4-yl)benzamide (CXD101), or a pharmaceutically acceptable salt thereof.
  • the IL- 15 superagonist is N-803.
  • the combination therapy may be in the form of a combined formulation for simultaneous administration of the therapeutically active components or they may be administered as separate formulations.
  • the separate formulations may be administered sequentially, separately or simultaneously.
  • the separate formulations of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt thereof, and the IL-15 superagonist are administered simultaneously (optionally repeatedly).
  • the separate formulations of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt thereof, and the IL-15 superagonist are administered sequentially (optionally repeatedly).
  • the separate formulations of N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H- pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt thereof, and the IL-15 superagonist are administered separately (optionally repeatedly).
  • N-(2-aminophenyl)-4-(1-[(1 ,3-dimethyl-1 H-pyrazol-4-yl)methyl]piperidin-4-yl)benzamide (CXD101/zabadinostat), or a pharmaceutically acceptable salt or solvate thereof may be administered to a subject by any appropriate or convenient route of administration, whether systemically/peripherally or topically (i.e. , at the site of desired action).
  • Routes of administration for CXD101 include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal
  • CXD101/zabadinostat is suitably administered orally.
  • routes of administration for the IL-15 supergonist include intravenous, subcutaneous, intramuscular, intradermal, or intranasal.
  • the IL-15 superagonist is proteinaceous, parenteral administration, including intravenous, is particularly suitable.
  • the combination treatment defined herein may be applied as the sole therapy for the treatment of the specified condition or it may involve, in addition to the combination therapy of the present invention, one or more additional therapies (including treatment with another therapeutic agent, surgery or other therapeutic interventions).
  • the other therapeutic agent used in combination with the combination therapy of the present invention will be one or more therapeutic agents used as the standard of care for the treatment or prevention of the disease, condition, or disorder concerned.
  • the other therapeutic agent may include, for example, another drug used for the treatment of the condition concerned, or an agent that modulates the biological response to the combination therapy of the invention.
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
  • the combination therapy of the present invention is particularly suitable for treating a proliferative disease or disorder. Accordingly, the antiproliferative combination therapy defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
  • Such chemotherapy may further include one or more of the following categories of anti-tumour agents:- other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); anti
  • inhibitors of growth factor function include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. (Critical reviews in oncology/haematology, 2005, Vol.
  • inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as A/-(3-chloro- 4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), /V-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6- acrylamido-A/-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (Cl 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the hepatocyte growth factor
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the combination therapy of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
  • a combination for use in the treatment of a cancer comprising a combination therapy of the invention as defined hereinbefore, and another anti-tumour agent.
  • a combination for use in the treatment of a proliferative condition such as cancer (for example a cancer involving a solid tumour), comprising a combination therapy of the invention as defined hereinbefore, and any one of the anti-tumour agents listed herein above.
  • FIG. 1A Depicts the experimental design showing dosing regimen.
  • Figure 1B Shows mean tumour volumes of female Balb/c mice implanted with Colon26 cells and then treated with control, N-803, zabadinostat, or combination. Error bars represent standard deviation.
  • Figure 1C Shows tumour volumes of individual female Balb/c mice implanted with Colon26 cells and then treated with control, N-803, zabadinostat, or combination.
  • Figure 1D Provides boxplots that represent mean tumour volumes at Day 13 of individual female Balb/c mice implanted with Colon26 cells and then treated with control, N-803, zabadinostat, or combination. **, P ⁇ 0.01 ; ***, P ⁇ 0.001 ; ***, P ⁇ 0.0001.
  • Figure 1 E Shows relative body weight changes of female Balb/c mice implanted with Colon26 cells and then treated with control, N-803, zabadinostat, or combination. Error bars represent standard deviation. Examples
  • Example 1 Assessment of the in vivo anti-tumour activity of N-803, an IL-15 superagonist complex, and CXD101 , the HDAC inhibitor zabadinostat, alone and in a combination treatment in the murine colon cancer model Colon26.
  • HDAC histone deacetylase
  • mice Female Balb/c mice were treated by subcutaneous unilateral injection of colon26 cells as follows: ell injection conditions
  • Vehicle x 5% DMSO, 0.5% Tween80 in wfi
  • Tumour volume at randomisation was between 50-100 mm 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant du N-(2-aminophényl)-4-(1-[(1,3-diméthyl-1H-pyrazol-4-yl)méthyl]pipéridin-4-yl) benzamide (CXD101), ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, et un superagoniste d'IL15, tel que N-803. La combinaison est appropriée pour être utilisée dans le traitement de troubles prolifératifs, tels que le cancer.
PCT/GB2024/052525 2023-10-03 2024-10-02 Combinaison de cxd101 et d'un superagoniste d'il-15 pour traiter des maladies prolifératives telles que le cancer Pending WO2025074090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2315149.1 2023-10-03
GBGB2315149.1A GB202315149D0 (en) 2023-10-03 2023-10-03 Combination therapy

Publications (1)

Publication Number Publication Date
WO2025074090A1 true WO2025074090A1 (fr) 2025-04-10

Family

ID=88696424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/052525 Pending WO2025074090A1 (fr) 2023-10-03 2024-10-02 Combinaison de cxd101 et d'un superagoniste d'il-15 pour traiter des maladies prolifératives telles que le cancer

Country Status (2)

Country Link
GB (1) GB202315149D0 (fr)
WO (1) WO2025074090A1 (fr)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
WO1997030035A1 (fr) 1996-02-13 1997-08-21 Zeneca Limited Derives de la quinazoline utilises comme inhibiteurs du vegf
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
WO1998013354A1 (fr) 1996-09-25 1998-04-02 Zeneca Limited Derives quinazolines et compositions pharmaceutiques les contenant
WO1999002166A1 (fr) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Utilisation de derives de colchinol comme agents de degradation vasculaire
WO2000040529A1 (fr) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Derives de colchinol utilises comme agents de degradation vasculaire
WO2000041669A2 (fr) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Agents de degradation vasculaire aux benzimidazoles
WO2000047212A1 (fr) 1999-02-10 2000-08-17 Astrazeneca Ab Derives de quinazoline utilises comme inhibiteurs de l'angiogenese
WO2001092224A1 (fr) 2000-05-31 2001-12-06 Astrazeneca Ab Derives d'indole possedant une activite endommageant les vaisseaux sanguins
WO2001094341A1 (fr) 2000-06-06 2001-12-13 Astrazeneca Ab Derives de la quinazoline pour le traitement de tumeurs
WO2002004434A1 (fr) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Derives de colchinol utilises comme agents de degradation vasculaire
WO2002008213A1 (fr) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Derives de colchinol utiles comme inhibiteurs de l'angiogenese
WO2007045844A1 (fr) 2005-10-19 2007-04-26 Astrazeneca Ab Composés de benzamide utiles comme inhibiteurs des histone désacétylases
US8163879B2 (en) 2007-05-11 2012-04-24 Altor Bioscience Corporation Fusion molecules and IL-15 variants
WO2012175222A1 (fr) 2011-06-24 2012-12-27 Cytune Immunocytokines à base d'il-15 et domaine sushi d'il-15rα
WO2015103928A1 (fr) 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Protéine dimérique hétérogène il-15 et ses utilisations
WO2018183821A1 (fr) 2017-03-31 2018-10-04 Altor Bioscience Corporation Alt-803 combiné à un anticorps anti-cd38 pour thérapies anticancéreuses
WO2019204592A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
US20210093625A1 (en) * 2019-09-27 2021-04-01 Celleron Therapeutics Limited Combination therapy

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022596A1 (fr) 1995-12-18 1997-06-26 Zeneca Limited Derives de quinazoline
WO1997030035A1 (fr) 1996-02-13 1997-08-21 Zeneca Limited Derives de la quinazoline utilises comme inhibiteurs du vegf
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
WO1998013354A1 (fr) 1996-09-25 1998-04-02 Zeneca Limited Derives quinazolines et compositions pharmaceutiques les contenant
WO1999002166A1 (fr) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Utilisation de derives de colchinol comme agents de degradation vasculaire
WO2000040529A1 (fr) 1999-01-07 2000-07-13 Angiogene Pharmaceuticals Ltd. Derives de colchinol utilises comme agents de degradation vasculaire
WO2000041669A2 (fr) 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Agents de degradation vasculaire aux benzimidazoles
WO2000047212A1 (fr) 1999-02-10 2000-08-17 Astrazeneca Ab Derives de quinazoline utilises comme inhibiteurs de l'angiogenese
WO2001092224A1 (fr) 2000-05-31 2001-12-06 Astrazeneca Ab Derives d'indole possedant une activite endommageant les vaisseaux sanguins
WO2001094341A1 (fr) 2000-06-06 2001-12-13 Astrazeneca Ab Derives de la quinazoline pour le traitement de tumeurs
WO2002004434A1 (fr) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Derives de colchinol utilises comme agents de degradation vasculaire
WO2002008213A1 (fr) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Derives de colchinol utiles comme inhibiteurs de l'angiogenese
WO2007045844A1 (fr) 2005-10-19 2007-04-26 Astrazeneca Ab Composés de benzamide utiles comme inhibiteurs des histone désacétylases
US8163879B2 (en) 2007-05-11 2012-04-24 Altor Bioscience Corporation Fusion molecules and IL-15 variants
WO2012175222A1 (fr) 2011-06-24 2012-12-27 Cytune Immunocytokines à base d'il-15 et domaine sushi d'il-15rα
WO2015103928A1 (fr) 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Protéine dimérique hétérogène il-15 et ses utilisations
WO2018183821A1 (fr) 2017-03-31 2018-10-04 Altor Bioscience Corporation Alt-803 combiné à un anticorps anti-cd38 pour thérapies anticancéreuses
WO2019204592A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
US20210093625A1 (en) * 2019-09-27 2021-04-01 Celleron Therapeutics Limited Combination therapy

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
"Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396
BERGAMASCHI, C.; WATSON, D. C.; VALENTIN, A.; BEAR, J.; PEER, C. J.; FIGG, W. D.; FELBER, B. K.; PAVLAKIS, G. N.: "Optimized Administration of hetlL-15 Expands Lymphocytes and Minimizes Toxicity in Rhesus Macaques.", CYTOKINE, vol. 108, 2018, pages 213 - 224, XP085399105, Retrieved from the Internet <URL:https://doi.org/10.1016/j.cyto.2018.01.011> DOI: 10.1016/j.cyto.2018.01.011
BLASZCZAK, W.LIU, G.ZHU, H.BARCZAK, W.SHRESTHA, A.ALBAYRAK, G.ZHENG, S.KERR, D.SAMSONOVA, A.LA THANGUE, N. B.: "Immune Modulation Underpins the Anti-cancer Activity of HDAC Inhibitors.", MOL ONCOL, vol. 15, no. 12, 2021, pages 3280 - 3298, Retrieved from the Internet <URL:https://doi.org/10.1002/1878-0261.12953>
CHU YAYA ET AL: "Enhancement of Expanded Natural Killer Cells Against Metastatic Osteosarcoma in Combination with Romidepsin (HDAC Inhibitor) or ALT-803 (IL-15 Superagonist)", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 23, no. 3, 1 March 2017 (2017-03-01), XP029931967, ISSN: 1083-8791, DOI: 10.1016/J.BBMT.2016.12.515 *
EPARDAUD, M.ELPEK, K. G.RUBINSTEIN, M. P.YONEKURA, A.BELLEMARE-PELLETIER, A.BRONSON, R.HAMERMAN, J. A.GOLDRATH, A. W.TURLEY, S. J.: "Interleukin-15/Interleukin-15R Alpha Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells", CANCER RES, vol. 68, no. 8, 2008, pages 2972 - 2983, Retrieved from the Internet <URL:https://doi.org/10.1158/0008-5472.CAN-08-0045>
EYRE, T. A.COLLINS, G. P.GUPTA, A.COUPE, N.SHEIKH, S.WHITTAKER, J.WANG, L. M.CAMPO, L.SOILLEUX, E.TYSOE, F.: "Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer.", CANCER, vol. 125, no. 1, 2019, pages 99 - 108, XP055758321, Retrieved from the Internet <URL:https://doi.org/10.1002/cncr.31791> DOI: 10.1002/cncr.31791
FUJII, R.JOCHEMS, C.TRITSCH, S. R.WONG, H. C.SCHLOM, J.HODGE, J. W.: "An IL-15 Superagonist/IL-15Ra Fusion Complex Protects and Rescues NK Cell-Cytotoxic Function from TGF-B1-Mediated Immunosuppression.", CANCER IMMUNOL IMMUNOTHER, vol. 67, no. 4, 2018, pages 675 - 689, XP036462535, Retrieved from the Internet <URL:https://doi.org/10.1007/s00262-018-2121-4> DOI: 10.1007/s00262-018-2121-4
GANESAN, A.: "Histone Modifications in Therapy", vol. 20, ACADEMIC, article "HDAC Inhibitors in Cancer Therapy", pages: 19 - 49
H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285
H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38
H. BUNDGAARD: "Design and Application of Pro-drugs", 1991, article "A Textbook of Drug Design and Development", pages: 113 - 191
HICKS KRISTIN C. ET AL: "Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy", CLINICAL CANCER RESEARCH, vol. 26, no. 3, 1 February 2020 (2020-02-01), US, pages 704 - 716, XP093219726, ISSN: 1078-0432, Retrieved from the Internet <URL:https://aacrjournals.org/clincancerres/article-pdf/26/3/704/2063662/704.pdf> DOI: 10.1158/1078-0432.CCR-19-0727 *
J. MED. CHEM., vol. 47, 2004, pages 6658 - 6661
KIM, P. S.; KWILAS, A. R.; XU, W.; ALTER, S.; JENG, E. K.; WONG, H. C.; SCHLOM, J.; HODGE,J. W.: "IL-15 Superagonist/IL-15RaSushi-Fc Fusion Complex (IL-15SA/IL-15RaSu-Fc;ALT-803) Markedly Enhances Specific Subpopulations of NK and Memory CD8+ T Cells,and Mediates Potent Anti-Tumor Activity against Murine Breast and Colon Carcinomas", ONCOTARGET, vol. 7, no. 13, 2016, pages 16130 - 16145, XP055403855, Retrieved from the Internet <URL:https://doi.org/10.18632/oncotarget.7470> DOI: 10.18632/oncotarget.7470
KNUDSEN KHODGE JSCHLOM JGAMEIRO S: "Rationale for IL-15 superagonists in cancer immunotherapy.", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 20, no. 7, 2020, pages 705 - 709, XP093030394, DOI: 10.1080/14712598.2020.1738379
LIU ET AL.: "The HDAC Inhibitor zabadinostat is a systemic regulator of adaptive immunity.", COMMUNICATIONS BIOLOGY, vol. 6, no. 102, 2023
MIYAZAKI TMAITI MSHEIBANI S: "Characterization and comparison of NKTR-255, a polymer conjugated IL-15 versus IL-15 superagonist.", POSTER PRESENTED AT: SITC ANNUAL
MORTIER EQUEMENER AVUSIO P ET AL.: "Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins", J BIOL CHEM., vol. 281, no. 3, 2006, pages 1612 - 1619, XP002394330, DOI: 10.1074/jbc.M508624200
N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692
ROBINSON, T. O.SCHLUNS, K. S.: "The Potential and Promise of IL-15 in Immuno-Oncogenic Therapies.", IMMUNOL LETT, vol. 190, 2017, pages 159 - 168, XP085196666, Retrieved from the Internet <URL:https://doi.org/10.1016/j.imlet.2017.08.010> DOI: 10.1016/j.imlet.2017.08.010
RUBINSTEIN MPKOVAR MPURTON JF ET AL.: "Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha", PROC NATL ACAD SCI U SA., vol. 103, no. 24, 2006, pages 9166 - 9171, XP002521796, DOI: 10.1073/pnas.0600240103
SAUNDERS, M. P.GRAHAM, J.CUNNINGHAM, D.PLUMMER, R.CHURCH, D.KERR, R.COOK, S.ZHENG, S.LA THANGUE, N.KERR, D.: "CXD101 and Nivolumab in Patients with Metastatic Microsatellite-Stable Colorectal Cancer (CAROSELL): A Multicentre, Open-Label, Single-Arm, Phase II Trial.", ESMO OPEN, vol. 7, no. 6, 2022, pages 100594, Retrieved from the Internet <URL:https://doi.org/10.1016/j.esmoop.2022.100594>
STERN ET AL., CRITICAL REVIEWS IN ONCOLOGY/HAEMATOLOGY, vol. 54, 2005, pages 11 - 29
T. HIGUCHIV. STELLA: "Pro-Drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
WALDMANN, T. A.: "The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy.", CANCER IMMUNOL RES, vol. 3, no. 3, 2015, pages 219 - 227, XP093188649, Retrieved from the Internet <URL:https://doi.org/10.1158/2326-6066.CIR-15-0009.> DOI: 10.1158/2326-6066.CIR-15-0009
ZHANG, M.YAO, Z.DUBOIS, S.JU, W.MULLER, J. R.WALDMANN, T. A.: "Interleukin-15 Combined with an Anti-CD40 Antibody Provides Enhanced Therapeutic Efficacy for Murine Models of Colon Cancer.", PROC NATL ACAD SCI U S A, vol. 106, no. 18, 2009, pages 7513 - 7518, XP055696302, Retrieved from the Internet <URL:https://doi.org/10.1073/pnas.0902637106> DOI: 10.1073/pnas.0902637106

Also Published As

Publication number Publication date
GB202315149D0 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
EP3212210B1 (fr) Polythérapie
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
US12453725B2 (en) Treatment of inflammatory disease
WO2025074090A1 (fr) Combinaison de cxd101 et d&#39;un superagoniste d&#39;il-15 pour traiter des maladies prolifératives telles que le cancer
CN101346137A (zh) 含有孔布勒塔斯塔坦与抗癌剂的组合物
CN114555053B (zh) 治疗乳腺癌的方法
Grem et al. Hypersensitivity reactions to trimetrexate
US20210093625A1 (en) Combination therapy
US20190134148A1 (en) Combination therapy
US20250360124A1 (en) Novel ras inhibitors
EP4536665A1 (fr) Nouveaux inhibiteurs de ras
WO2024004656A1 (fr) Effet d&#39;inhibition d&#39;un événement indésirable lié à l&#39;immunité
EP4536360A1 (fr) Nouveaux inhibiteurs de ras
EP4536646A1 (fr) Nouveaux inhibiteurs de ras
WO2023242097A1 (fr) Dérivés de mitoxanthrone en tant qu&#39;inhibiteurs de ras
WO2023242101A1 (fr) Nouveaux inhibiteurs de ras
EP4536635A1 (fr) Nouveaux inhibiteurs de ras
WO2023242104A1 (fr) Dérivés de diaminoacridine en tant qu&#39;inhibiteurs de ras
EP4654961A1 (fr) Nouveaux mélanges en tant qu&#39;inhibiteurs de ras destinés à être utilisés dans le traitement de maladies prolifératives et génétiques
Counter-Regulation Chronic Chemoimmunotherapy Achieves
CA3071550A1 (fr) Traitement du cancer par stimulation de la production d&#39;il-12
HK1239551B (en) Combination therapy
HK1239551A1 (en) Combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24789938

Country of ref document: EP

Kind code of ref document: A1